Kolexia
Pujade-Lauraine Eric Oncologie médicale
Pujade-Lauraine Eric
Oncologie médicale
Hôpital Hôtel-Dieu Paris
Paris, France
350 Activités
0 Followers
Scientifique
Digital
Production scientifique
Activités par an
Expertise
Sujets de recherche
{{person.topmesh1.name}} Tumeurs de l'ovaire Carcinome épithélial de l'ovaire Récidive tumorale locale Carcinomes Tumeurs épithéliales épidermoïdes et glandulaires Tumeurs du sein Tumeurs de la trompe de Fallope Tumeurs du col de l'utérus Tumeurs de l'appareil génital féminin

Collaborateurs

Voir plus
Ray Isabelle
Ray Isabelle
Centre Léon-Bérard, Lyon, France
Selle Frederic
Selle Frederic
Institut Caroline Malvesin, Paris, France
Joly Florence
Joly Florence
Hôpital Côte de Nacre, Caen, France
Lortholary Alain
Lortholary Alain
Alek Onco, Nantes, France

Industries

Voir plus
GSK
7 collaboration(s)
Dernière en 2022
Roche
6 collaboration(s)
Dernière en 2023
MSD
2 collaboration(s)
Dernière en 2021
{{person.topindus4.name}}
{{person.topindus4.tot}} collaboration(s)
Dernière en {{person.topindus4.last}}

Dernières activités

Voir plus
Olaparib Treatment in BRCA Mutated Ovarian Cancer Patients After Complete or Partial Response to Platinum Chemotherapy: Phase III Randomised, Double Blind, Placebo Controlled Study of Olaparib Maintenance Monotherapy in Platinum Sensitive Relapsed BRCA Mutated Ovarian Cancer Patients With a Complete or Partial Response Following Platinum Based Chemotherapy
Essai Clinique (AstraZeneca)   15 janvier 2024
Poor Concordance Between Cancer Antigen-125 and RECIST Assessment for Progression in Patients With Platinum-Sensitive Relapsed Ovarian Cancer on Maintenance Therapy With a Poly(ADP-ribose) Polymerase Inhibitor.
Journal of clinical oncology : official journal of the American Society of Clinical Oncology   12 janvier 2024
ATALANTE: A Randomized, Double-blinded, Phase III Study of Atezolizumab Versus Placebo in Patients With Late Relapse of Epithelial Ovarian, Fallopian Tube, or Peritoneal Cancer Treated by Platinum-based Chemotherapy and Bevacizumab
Essai Clinique (Roche)   02 janvier 2024
GIInger predicts homologous recombination deficiency and patient response to PARPi treatment from shallow genomic profiles.
Cell reports. Medicine   22 décembre 2023
Updated progression-free survival and final overall survival with maintenance olaparib plus bevacizumab according to clinical risk in patients with newly diagnosed advanced ovarian cancer in the phase III PAOLA-1/ENGOT-ov25 trial.
International journal of gynecological cancer : official journal of the International Gynecological Cancer Society   21 décembre 2023
Discordance between GCIG CA-125 progression and RECIST progression in the CALYPSO trial of patients with platinum-sensitive recurrent ovarian cancer.
British journal of cancer   14 décembre 2023
Shallow whole genome sequencing approach to detect Homologous Recombination Deficiency in the PAOLA-1/ENGOT-OV25 phase-III trial.
Oncogene   09 novembre 2023
Validation of the Clinical Use of GIScar, an Academic-developed Genomic Instability Score Predicting Sensitivity to Maintenance Olaparib for Ovarian Cancer.
Clinical cancer research : an official journal of the American Association for Cancer Research   02 novembre 2023
Maintenance olaparib rechallenge in patients with platinum-sensitive relapsed ovarian cancer previously treated with a PARP inhibitor (OReO/ENGOT-ov38): a phase IIIb trial.
Annals of oncology : official journal of the European Society for Medical Oncology   04 octobre 2023
Left Ventricular Ejection Fraction in Patients With Ovarian Cancer Treated With Avelumab, Pegylated Liposomal Doxorubicin, or Both.
The oncologist   04 octobre 2023